

Ranee Mehra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8367413/publications.pdf>

Version: 2024-02-01

37
papers

4,873
citations

331670

21
h-index

361022

35
g-index

37
all docs

37
docs citations

37
times ranked

6633
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311). <i>Journal of Clinical Oncology</i> , 2022, 40, 138-149.	1.6	162
2	Patient and Caregiver Preferences for First-Line Treatments of Metastatic Non-Small Cell Lung Cancer: A Discrete Choice Experiment. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 123-135.	1.8	2
3	Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. , 2022, 10, e003026.		38
4	Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 469-478.	2.3	2
5	Comparison of efficacy and toxicity of chemoradiation regimens for head and neck squamous cell carcinoma primary treatment. <i>Head and Neck</i> , 2022, 44, 749-759.	2.0	2
6	Costâ€effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 595-607.	1.4	1
7	Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. <i>Journal of the National Cancer Institute</i> , 2021, 113, 171-181.	6.3	25
8	Treatment modalities, adverse events, and survival outcomes in older patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2021, 43, 3935-3945.	2.0	4
9	A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311. <i>Oral Oncology</i> , 2020, 110, 104797.	1.5	32
10	Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 2149-2156.	2.8	6
11	Emerging immune checkpoint inhibitors for the treatment of head and neck cancers. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 501-514.	2.4	7
12	Concurrent Definitive Immunoradiotherapy for Patients with Stage IIIâ€IV Head and Neck Cancer and Cisplatin Contraindication. <i>Clinical Cancer Research</i> , 2020, 26, 4260-4267.	7.0	35
13	Immunotherapy in Lung Cancer: From a Minor God to the Olympus. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 69-92.	1.6	15
14	New Targets in Lung Cancer (Excluding EGFR, ALK, ROS1). <i>Current Oncology Reports</i> , 2020, 22, 48.	4.0	39
15	<p>Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3047-3059.	2.0	25
16	Liquid biopsy tracking of lung tumor evolutions over time. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1099-1108.	3.1	50
17	RET fusions in solid tumors. <i>Cancer Treatment Reviews</i> , 2019, 81, 101911.	7.7	150
18	PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2019, 91, 69-78.	1.5	25

#	ARTICLE	IF	CITATIONS
19	Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2019, 25, 3430-3442.	7.0	51
20	Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 393, 156-167.	13.7	1,153
21	Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012. <i>British Journal of Cancer</i> , 2018, 119, 153-159.	6.4	329
22	Targeting phosphoinositide 3-kinase (PI3K) in head and neck squamous cell carcinoma (HNSCC). <i>Cancers of the Head & Neck</i> , 2018, 3, 3.	6.2	58
23	Nivolumab-induced autoimmune diabetes mellitus presenting as diabetic ketoacidosis in a patient with metastatic lung cancer. , 2017, 5, 40.		99
24	Impact of baseline patient-reported dysphagia on acute gastrostomy placement in patients with head and neck squamous cell carcinoma undergoing definitive radiation. <i>Head and Neck</i> , 2016, 38, E1318-24.	2.0	7
25	Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. <i>Lancet Oncology</i> , The, 2016, 17, 956-965.	10.7	1,369
26	Early oral tongue cancer initially managed with surgery alone: Treatment of recurrence. <i>World Journal of Otorhinolaryngology - Head and Neck Surgery</i> , 2016, 2, 193-197.	1.6	7
27	The Impact of Radiation Treatment Time on Survival in Patients With Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 967-975.	0.8	77
28	Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort. <i>Journal of Clinical Oncology</i> , 2016, 34, 3838-3845.	1.6	715
29	EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2486-2497.	4.1	42
30	Systemic Therapy for Squamous Cell Carcinoma of the Head and Neck. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 437-454.	1.5	11
31	Targeting brain metastases in ALK-rearranged non-small-cell lung cancer. <i>Lancet Oncology</i> , The, 2015, 16, e510-e521.	10.7	160
32	Pre-treatment tumor-specific growth rate as a temporal biomarker that predicts treatment failure and improves risk stratification for oropharyngeal cancer. <i>Oral Oncology</i> , 2015, 51, 1034-1040.	1.5	15
33	HPV-associated lung cancers: an international pooled analysis. <i>Carcinogenesis</i> , 2014, 35, 1267-1275.	2.8	57
34	Management of Human Papillomavirus-Positive and Human Papillomavirus-Negative Head and Neck Cancer. <i>Seminars in Radiation Oncology</i> , 2012, 22, 194-197.	2.2	31
35	New Agents in the Treatment for Malignancies of the Salivary and Thyroid Glands. <i>Hematology/Oncology Clinics of North America</i> , 2008, 22, 1279-1295.	2.2	8
36	The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck. <i>Clinical Advances in Hematology and Oncology</i> , 2008, 6, 742-50.	0.3	58

#	ARTICLE	IF	CITATIONS
37	Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials. Expert Opinion on Biological Therapy, 2006, 6, 951-962.	3.1	6